Health Canada approves expanded uses for Tandem’s t:slim X2 insulin pump

Tandem Diabetes Care received Health Canada clearance for its t:slim X2 pump with Control‑IQ+ technology, adding compatibility with Abbott’s FreeStyle Libre 3 Plus sensor and new indications for adults with type 2 diabetes and for pregnant individuals with type 1 diabetes. The company said the expanded features will be commercially available in Canada in the second quarter of 2027. Clinical data supporting the approvals showed a 0.9 percentage‑point A1C reduction versus 0.3 percentage‑points for controls in type 2 patients, and a 12.6 % increase in time‑in‑target glucose range (about three extra hours per day) for pregnant users.

The approvals open a larger Canadian market for Tandem’s automated insulin delivery system, potentially boosting revenue once the Q2 2027 launch occurs (the company expects). Investors should watch for sales growth in Canada as the new indications become available.

  • 1Health Canada approved a license amendment for the t:slim X2 pump with Control‑IQ+ technology.
  • 2The approval adds compatibility with Abbott’s FreeStyle Libre 3 Plus sensor.
  • 3New indications include use by adults with type 2 diabetes and by people with type 1 diabetes during pregnancy.
  • 4Commercial availability in Canada is expected in the second quarter of 2027.
  • 5In the 2IQP trial, patients using Control‑IQ+ achieved a 0.9 % reduction in A1C versus 0.3 % in the control arm.
  • 6In the CIRCUIT trial, pregnant participants using the pump spent 12.6 % more time in the target glucose range (about three additional hours per day).

Sources